AMLX three-lens brief
Evidence-based stock research on AMLX. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA above 200-day MA (golden-cross regime); price above both. · Currently unprofitable on a trailing basis — no P/E multiple available.
- 50-day MA above 200-day MA (golden-cross regime); price above both.
- Outperforming SPY by 58.8pp over 30 days.
- Currently unprofitable on a trailing basis — no P/E multiple available.
- Analyst mean target $42.36 — 32% above current (11 analysts).
- Negative free cash flow last quarterly (-$77.32M).
AMLX closed at $32.09 (-0.96%) as of 2026-09-11. Market cap: $3.58B. Price is above the 50-day MA and above the 200-day MA. Positives: 50-day MA above 200-day MA (golden-cross regime); price above both.; outperforming SPY by 58.8pp over 30 days.. Concerns: currently unprofitable on a trailing basis — no P/E multiple available.; negative free cash flow last quarterly (-$77.32M).. Last quarter: net income -$43.42M, free cash flow -$77.32M.
Why three lenses on AMLX, not one.
A single reasoning model has blind spots it doesn’t know about. We examine AMLXacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/AMLX" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath AMLX brief"></iframe>